Harvard Apparatus Regenerative Technology Inc HRGN Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.91 down $0.39, 16.96% at close Nov 6
Last close · Previous close $2.30
- 52-week change
- down $0.02, 1.04%Price only
- Distributions
- $0.00Per share, last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.91down $0.34, 15.11%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.30Nov 5
- Volume2.64KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.60KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.96 to $2.46; now $1.91
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
HRGN beat the S&P 500 in 1 of 7 periods.
| Period | HRGN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HRGN: down 15.1% S&P 500: down 5.6% | HRGN trailed the S&P 500 by 9.5 percentage points Trailed |
| 3M | HRGN: up 91.0% S&P 500: down 4.1% | HRGN beat the S&P 500 by 95.1 percentage points Beat |
| YTD | HRGN: up 3.8% S&P 500: up 8.7% | HRGN trailed the S&P 500 by 4.9 percentage points Trailed |
| 1Y | HRGN: down 1.0% S&P 500: up 10.9% | HRGN trailed the S&P 500 by 11.9 percentage points Trailed |
| Long term | ||
| 3Y | HRGN: down 68.2% S&P 500: up 75.0% −31.7% vs +20.5% a year | HRGN trailed the S&P 500 by 143.2 percentage points Trailed |
| 5Y | HRGN: down 26.5% S&P 500: up 67.8% −6.0% vs +10.9% a year | HRGN trailed the S&P 500 by 94.3 percentage points Trailed |
| 10Y | HRGN: up 141.8% S&P 500: up 313.1% +9.2% vs +15.2% a year | HRGN trailed the S&P 500 by 171.3 percentage points Trailed |
$10,000 invested in HRGN 10 years ago (Nov 4, 2016) would be worth about $24,177 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
HRGN beat the S&P 500 in 1 of 7 periods.
| Period | HRGN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | HRGN: down 15.1% S&P 500: down 5.6% | HRGN trailed the S&P 500 by 9.5 percentage points Trailed |
| 3M | HRGN: up 91.0% S&P 500: down 4.3% | HRGN beat the S&P 500 by 95.3 percentage points Beat |
| YTD | HRGN: up 3.8% S&P 500: up 7.8% | HRGN trailed the S&P 500 by 4.0 percentage points Trailed |
| 1Y | HRGN: down 1.0% S&P 500: up 9.7% | HRGN trailed the S&P 500 by 10.7 percentage points Trailed |
| Long term | ||
| 3Y | HRGN: down 68.2% S&P 500: up 68.8% −31.7% vs +19.1% a year | HRGN trailed the S&P 500 by 137.0 percentage points Trailed |
| 5Y | HRGN: down 26.5% S&P 500: up 56.9% −6.0% vs +9.4% a year | HRGN trailed the S&P 500 by 83.4 percentage points Trailed |
| 10Y | HRGN: up 141.8% S&P 500: up 252.6% +9.2% vs +13.4% a year | HRGN trailed the S&P 500 by 110.8 percentage points Trailed |
$10,000 invested in HRGN 10 years ago (Nov 4, 2016) would be worth about $24,177 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$7.25
Closing high on . Now 73.7% below that record.
Split-adjusted daily closes since Jan 4, 2016.
Stock splits
HRGN hasn’t split since its price history begins in 2016.
About Harvard Apparatus Regenerative Technology Inc
We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next-generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrifice of another of the patient’s own organs or permanent artificial implants. We conducted the world’s first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure demonstrated that our technology was able to successfully regenerate esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube. HRGN has 13 issued U.S. patents, 2 issued in China, 1 issued in Japan, 2 issued in Europe and 2 orphan-drug designations which can provide seven years of market exclusivity in the US market after market approval from the FDA and 1 EMA orphan drug designation, which can provide ten years of market exclusivity in the European market after market approval from the EMA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
HRGN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
HRGN stock FAQ
What is HRGN stock’s price today?
Harvard Apparatus Regenerative Technology (HRGN) traded at $1.91 at the close on , down $0.39 (16.96%) from the previous close of $2.30. Over the past 52 weeks it has traded between $0.96 and $2.46.
If you invested $1,000 in HRGN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in HRGN on would be worth about $2,418 at the close on , a total return of +141.8%. The same $1,000 would be worth $735 if invested five years ago and $990 if invested one year ago. Past performance doesn’t predict future returns.
What is Harvard Apparatus Regenerative Technology’s market cap?
Harvard Apparatus Regenerative Technology’s market capitalization is about $3.7 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.91 (how market cap works).
Does HRGN pay a dividend?
Harvard Apparatus Regenerative Technology hasn’t paid a dividend in the last twelve months.
What is HRGN’s 52-week high and low?
Over the past 52 weeks HRGN has traded as low as $0.96 and as high as $2.46. At $1.91 at the close on , it is 22.4% below that high and 99.0% above the low.
What is HRGN’s all-time high?
HRGN’s highest closing price was $7.25 on , adjusted for stock splits. At $1.91 at the close on , it is 73.7% below that record.
Has HRGN stock ever split?
No. HRGN hasn’t split since its price history begins in 2016.
How has HRGN stock performed?
Including dividends and measured to the close on , HRGN has returned +3.8% so far this year and −1.0% over the past year, and −26.5% over five years (−6.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Harvard Apparatus Regenerative Technology in?
Harvard Apparatus Regenerative Technology is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does HRGN trade on?
Harvard Apparatus Regenerative Technology trades on the PINK under the ticker symbol HRGN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.